cenicriviroc (TBR-652) / Dong-A, AbbVie, Takeda  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cenicriviroc (TBR-652) / Takeda, AbbVie
NCT01827540: Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

Completed
1
20
US
Cenicriviroc, CVC, Dolutegravir, DTG, Midazolam, Dormicum, Hypnovel, Versed
Tobira Therapeutics, Inc., ViiV Healthcare
HIV-infection/AIDS
05/13
05/13
NCT02120547: Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

Completed
1
31
US
Cenicriviroc in mild liver impaired, CVC, Cenicriviroc in moderate liver impaired
Tobira Therapeutics, Inc.
Liver Insufficiency
07/14
08/14
NCT02342067: Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Completed
1
20
US
Cenicriviroc, CVC 150 mg, Pioglitazone, PGZ 45 mg
Tobira Therapeutics, Inc.
Healthy
03/15
04/15
NCT02685462: Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

Completed
1
36
US
Rosuvastatin, Rosuvastatin 20 mg, Atorvastatin, Atorvastatin 20 mg, Simvastatin, Simvastatin 20 mg, Digoxin, Digoxin 0.25 mg, Caffeine, Caffine 200 mg
Tobira Therapeutics, Inc.
Healthy
02/16
02/16
NCT02684799: Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Completed
1
48
US
Cenicriviroc, Cenicriviroc 150 mg, Omeprazole, Omeprazole 20 mg, Omeprazole 40 mg, Famotidine, Famotidine 40 mg
Tobira Therapeutics, Inc.
Healthy
04/16
04/16
NCT03376841: Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Completed
1
16
US
Cenicriviroc, CVC
Allergan
Hepatic Impairment
11/17
12/17

Download Options